CRA was retained by the plaintiff in a patent dispute to determine the amount of reasonable royalties due as a result of infringement of a patent by a major medical device company. CRA’s intellectual property expert evaluated the economic and technological comparability of multiple license agreements, the feasibility of non-infringing alternatives, and the Georgia-Pacific factors to determine the appropriate reasonable royalty rate. Dr. Sean Sheridan submitted an expert report and provided testimony in deposition. The case settled prior to trial.
Recent trends in Rule 702 decisions – 2024
In this CRA Insights, we update the Rule 702 decision trends in last year’s Insights with 2023 data.[1] We also provide descriptions of four specific...